AbCellera Biologics launched an underwritten public offering targeting $200 million to fund its menopause antibody program. The company plans to raise proceeds through common shares and pre-funded warrants, with ABCL635 as the lead clinical asset receiving earmarked support for continued trials. AbCellera is also developing ABCL365, an investigational non-hormonal antibody intended to treat moderate-to-severe vasomotor symptoms by targeting the neurokinin 3 receptor (NK3R). The financing is framed as supporting clinical advancement and working capital needs. For investors and development teams, the offering indicates continued market demand for stage-appropriate immunology assets, while also highlighting the capital intensity typical of antibody programs progressing through late clinical development.